No clinical benefit of high dose corticosteroid administration in patients with COVID-19 : A preliminary report of a randomized clinical trial
Copyright © 2021 Elsevier B.V. All rights reserved..
The aim of this study was to evaluate the clinical effects of dexamethasone administration in patients with mild to moderate acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). The study included 50 patients who were randomly assigned to the dexamethasone group or control group. Dexamethasone was administered at a dose of 20 mg/day from day 1-5 and then at 10 mg/day from day 6-10. The need for invasive mechanical ventilation, death rate, duration of clinical improvement, length of hospital stay, and radiological changes in the computed tomography scan were assessed. The results revealed that 92% and 96% of patients in the dexamethasone and control groups, respectively, required noninvasive ventilation (P = 0.500). Among them, 52% and 44% of patients in the dexamethasone and control groups, respectively, required invasive mechanical ventilation (P = 0.389). At the end of the study, 64% of patients in the dexamethasone group and 60% of patients in the control group died (P = 0.500); the remaining patients were discharged from the hospital during the 28-day follow-up period. The median length of hospital stay was 11 days in the dexamethasone group and 6 days in the control group (P = 0.036) and the median length of hospital stay was 7 days in the dexamethasone group and 3 days in the control group (P < 0.001). No significant differences were observed in the other outcomes. This study showed that corticosteroid administration had no clinical benefit in patients with COVID-19-induced mild to moderate ARDS.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:897 |
---|---|
Enthalten in: |
European journal of pharmacology - 897(2021) vom: 15. Apr., Seite 173947 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jamaati, Hamidreza [VerfasserIn] |
---|
Links: |
---|
Themen: |
7S5I7G3JQL |
---|
Anmerkungen: |
Date Completed 18.03.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejphar.2021.173947 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321658361 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321658361 | ||
003 | DE-627 | ||
005 | 20231225180340.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejphar.2021.173947 |2 doi | |
028 | 5 | 2 | |a pubmed24n1072.xml |
035 | |a (DE-627)NLM321658361 | ||
035 | |a (NLM)33607104 | ||
035 | |a (PII)S0014-2999(21)00100-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jamaati, Hamidreza |e verfasserin |4 aut | |
245 | 1 | 0 | |a No clinical benefit of high dose corticosteroid administration in patients with COVID-19 |b A preliminary report of a randomized clinical trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
520 | |a The aim of this study was to evaluate the clinical effects of dexamethasone administration in patients with mild to moderate acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). The study included 50 patients who were randomly assigned to the dexamethasone group or control group. Dexamethasone was administered at a dose of 20 mg/day from day 1-5 and then at 10 mg/day from day 6-10. The need for invasive mechanical ventilation, death rate, duration of clinical improvement, length of hospital stay, and radiological changes in the computed tomography scan were assessed. The results revealed that 92% and 96% of patients in the dexamethasone and control groups, respectively, required noninvasive ventilation (P = 0.500). Among them, 52% and 44% of patients in the dexamethasone and control groups, respectively, required invasive mechanical ventilation (P = 0.389). At the end of the study, 64% of patients in the dexamethasone group and 60% of patients in the control group died (P = 0.500); the remaining patients were discharged from the hospital during the 28-day follow-up period. The median length of hospital stay was 11 days in the dexamethasone group and 6 days in the control group (P = 0.036) and the median length of hospital stay was 7 days in the dexamethasone group and 3 days in the control group (P < 0.001). No significant differences were observed in the other outcomes. This study showed that corticosteroid administration had no clinical benefit in patients with COVID-19-induced mild to moderate ARDS | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Corticosteroids | |
650 | 4 | |a Dexamethasone | |
650 | 4 | |a SARS-Cov-2 | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
700 | 1 | |a Hashemian, Seyed MohammadReza |e verfasserin |4 aut | |
700 | 1 | |a Farzanegan, Behrooz |e verfasserin |4 aut | |
700 | 1 | |a Malekmohammad, Majid |e verfasserin |4 aut | |
700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
700 | 1 | |a Marjani, Majid |e verfasserin |4 aut | |
700 | 1 | |a Moniri, Afshin |e verfasserin |4 aut | |
700 | 1 | |a Abtahian, Zahra |e verfasserin |4 aut | |
700 | 1 | |a Haseli, Sara |e verfasserin |4 aut | |
700 | 1 | |a Mortaz, Esmaeil |e verfasserin |4 aut | |
700 | 1 | |a Dastan, Alireza |e verfasserin |4 aut | |
700 | 1 | |a Mohamadnia, Abdolreza |e verfasserin |4 aut | |
700 | 1 | |a Vahedi, Abdolbaset |e verfasserin |4 aut | |
700 | 1 | |a Monjazebi, Fatemeh |e verfasserin |4 aut | |
700 | 1 | |a Yassari, Fatemeh |e verfasserin |4 aut | |
700 | 1 | |a Fadaeizadeh, Lida |e verfasserin |4 aut | |
700 | 1 | |a Saffaei, Ali |e verfasserin |4 aut | |
700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 897(2021) vom: 15. Apr., Seite 173947 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
773 | 1 | 8 | |g volume:897 |g year:2021 |g day:15 |g month:04 |g pages:173947 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2021.173947 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 897 |j 2021 |b 15 |c 04 |h 173947 |